Despite the conclusive evidence for FASN involvement in tumor metabolic reprogramming, the clinical scenario has remained uncompleted regarding first generation inhibitors, although it is improving with next-generation FASN inhibitors [172]. This evidence concerns the gene FASN and neoplasm.